International Clinical Trial: Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07531095) titled 'Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)' on April 9.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Amgen

Condition: Small Cell Lung Cancer

Intervention: Drug: ZL-1310 Drug: Tarlatamab

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: May 5, 2026

Target Sample Size: 160

To know more, visit https://clinicaltrials.gov/study/NCT07531095

Disclaimer: Curated by HT Syndicatio...